drugset
drugset / Trial / NCT00608361

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

NCT00608361 ↗

Phase 1 Completed 80 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of dasatinib in treating patients with solid tumors or lymphomas that are metastatic or cannot be removed by surgery. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2008-10
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject dasatinib anhydrous Small molecule — Oral

Indications

B-cell adult acute lymphocytic leukemia Burkitt lymphoma Hodgkins lymphoma MALT lymphoma T-cell adult acute lymphocytic leukemia T-cell large granular lymphocyte leukemia Waldenstrom macroglobulinemia adult T-cell leukemia/lymphoma adult hepatocellular carcinoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma chronic lymphocytic leukemia/small lymphocytic lymphoma extranodal nasal NK/T cell lymphoma grade III lymphomatoid granulomatosis hairy cell leukemia hepatosplenic T-cell lymphoma intraocular lymphoma large-cell immunoblastic lymphoma mantle cell lymphoma mycosis fungoides and variants nodal marginal zone B-cell lymphoma primary cutaneous B-cell lymphoma small intestine lymphoma splenic marginal zone lymphoma testicular lymphoma